Recce Ltd has released a press release.
Approval to Start Phase I/II Diabetic Foot Ulcer Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Anti-Infective Portfolio Update and Webinar details
- Pause in trading
- R327 COVID Study Update
- Expansion and Acceleration of Clinical Programs
- Appendix 4E
Later from Recce Pharmaceuticals
- Anti-Infective Research Unit est. at Murdoch Childrens
- Australian Patent to be Granted for RECCE Anti-Infectives
- JP Morgan Healthcare Conference
- A$6.21m Received from R&D Rebate Payments
- Recce Selects CMAX for Phase I/II UTI Clinical Trial
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals